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SUMMARY 
 
Colorectal cancer remains one of the leading causes of cancer-related deaths in  
Singapore. The colorectal cancer is a heterogeneous disease. There are at least 
three major molecular pathways to colorectal cancer development. These 
include the predominant chromosomal instability (CIN) pathway, which 
accounts for up to 85% of cases. Secondly, there is the CpG island methylator 
phenotype (CIMP) pathway that is the other major pathway to sporadic 
colorectal cancers. Finally, there is the pure MSI pathway which results from 
germline mutation of a DNA mismatch repair (MMR) gene. Hereditary 
nonpolyposis colorectal cancer (HNPCC) develops via the pure MSI pathway. 
 
In the last few years, there has been a growing hypothesis that human 
cancer should be considered as an alternative form of stem cell disease. This 
concept states that tumours are not to be viewed as simple monoclonal 
expansions of transformed cells - but rather as complex tissues where 
abnormal growth is driven by a minority of cancer stem cells. These cancer 
stem cells possess tumour-related features such as uncontrolled growth and the 
ability to form metastases. They also maintain their inherent stem cell capacity 
to self-renew and differentiate. 
 
In this thesis, the molecular and clinical significance of cancer stem-
cell markers and its related proteins in colorectal cancers were investigated. 
Tissue microarray analysis were combined with an automated image scanning 
  vi 
and analysis platform to examine the immunohistochemical expression of a 
panel of nine markers, of which three are cancer stem cell related proteins. In 
addition, BRAF and KRAS mutation analysis and microsatellite instability 
testing were performed to explore the possibility of any implications between 
cancer stem cells and the pathways responsible for colorectal cancer 
development. Lastly, possible relations to therapeutic responses were also 
examined.  
 
In this thesis, the findings indicated that expression of CD133, a 
putative cancer stem cell protein marker, possesses predictive significance of 
chemoresistance in colorectal cancer tumours. Independent prognostic 
significance in p27, as well as cancer stem cell related proteins CD133 and 
OCT-4 were observed.  In addition, no correlations between cancer stem cells 
proteins and BRAF or KRAS mutations. To achieve these biological 
observations with clinical implications, several steps were taken, namely a) a 
hospital-based model for translational research making use of amplifiable 
DNA from formalin-fixed paraffin-embedded tissue blocks archived as early 
as 50 years ago; and b) a reliable method for the use of computer assisted IHC 
scoring which achieved a high level of concordance with manual human 
observer scoring.  
 
In summary, the work of this thesis presents, for the first time, the 
predictive significance of a cancer stem cell marker and its lack of correlation 
with BRAF, KRAS or microsatellite instability genotypes. By doing so, it 
  vii 
allowed the setup and validation of a comprehensive platform to expand the 
possibilities for molecular pathologic studies in large cohort-centric 
epidemiological research. The results of this thesis provide a basis for high-
throughput standardization of immunohistochemical markers, which would 
enable the identification, or validation of tissue-based biomarkers. This is a 
valuable tool in determining prognosis and prediction of treatment responses 
in Asian colorectal cancer patients for future studies in the local institutions. 
  viii 
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CHAPTER 1: INTRODUCTION 
 
1.1 Incidence and Survival Rates of Colorectal Cancer 
 
Colorectal cancer is a common cause of cancer-related deaths. The World 
Health Organisation estimates that more than 945,000 people develop 
colorectal cancer annually worldwide with a death rate of 492,000 (Potter et 
al., 1999; Weitz et al., 2005). The cumulative lifetime risk of developing 
colorectal cancer and death is approximately 6% and 2.5%, respectively (Seow 
et al., 2002; Lindor et al., 2005). Incidence rates vary amongst developing and 
developed countries (Potter et al.,1999; Pisani et al., 2002). In Singapore, 
colorectal cancer is the second most common cancer for both men and women, 
after lung and breast cancer, respectively, and occurs with almost equal 
frequency in both gender groups (Huang et al., 1999; Seow et al., 2002).  
Colorectal cancer mortality has doubled in both men and women over the past 
three decades in Singapore (Seow et al., 2002).  
 
The survival rate of colorectal cancer patients vary accordingly to the 
stage of the disease determined at the time of diagnosis (Table 1). As it is with 
any type of cancer, prognosis of the patient is better at the earlier stage. For 
stage 1 colorectal cancer patients, surgical resection is associated with 95% 
five-year survival rate (O’Connell et al., 2004). Subsequently, the survival rate 
decreases.  
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Table 1. TNM classification according to the 7th edition of the American 
Journal of Colorectal Cancer (AJCC) Staging Manual. The table below 
summarizes the characteristics for each classifications adapted from Edge et 
al. (Edge et al., 2010). 
 
 T (Primary tumour)  N (Nodal 
status) 
 M (Distant 
metastases) 
TX Primary tumour cannot be 
assessed 







T0 No evidence of primary 
tumour 
N0 No regional 
lymph node 
metastasis 
MO No distant 
metastases 




metastasis in one 
organ 
T1 Tumour invades submucosa N1b Metastasis in 2 to 




more than one 
organ 
T2 Tumour invades muscularis 
propria 






T3 Tumour invades through 
muscularis propria into 
subserosa or into the non-
perionealized pericolic tissues 
N2a Metastasis in 4 to 
5 regional lymph 
nodes 
  
T4a Tumour invades visceral 
peritoneum 
    




Table 2. Five-year overall survival rate according to AJCC staging. The 
table below shows the 5-year overall survival percentage based on figures 
adapted from Weitz et al. (Weitz et al., 2005) 
 
AJCC 
(Edge et al., 2010) 
TNM 
(Edge et al., 2010) 
5-year overall survival 
(Weitz et al., 2005) 
Stage I T1, N0, M0 
T2, N0, M0 
80-95% 
Stage IIa T3, N0, M0 72-75% 
Stage IIb T4, N0, M0 65-66% 
Stage IIIa T1-2, N1, M0 55-60% 
Stage IIIb T3-4, N1, M0 35-42% 
Stage IIIc Any T, N2, M0 25-27% 
Stage IV Any T, Any N, M1 0-7% 
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The largest decrease in the five-year survival rate occurs between stage IIIC 
and stage IV, from 44% to 8%, respectively (O’Connell et al., 2004). This is 
primarily due to the presentation of metastasis. 
 
 
1.2 Hallmarks of Cancer Development 
 
The “chromosomal missegregation” is widely regarded as the fundamental 
basis of cancer (Nowell et al., 1990) - that tumours expand as a clone from a 
single altered cell and that ‘progression’ is due to results of somatic, genetic or 
epigenetic changes (Nowell, et al., 2002). Around five to seven successive 
mutations have been estimated in order to allow tumour growth, invasion and 
metastasis from normal cells (Fearon et al., 1990; Luebeck et al, 2002; 
Renehan et al., 2007). In colorectal cancer, these forms of “stepwise 
mutations” are best illustrated by the identification of sequential mutations of 
APC, KRAS, SMAD4 and p53 in defined stages of tumourigenesis, transiting 
from normal mucosa to carcinoma (Fearon et al., 1990; Frattini et al., 2004). 
Several other genes have also been identified as cancer “susceptibility genes” 
in this progression (Kouraklis et al., 2003; Atasoy et al., 2004; Ogino et al., 
2008). Interesting, although most of these genes appear to have different 
functional roles in different tumours, the loss or their abnormal functions will 
allow most cancers to acquire a similar set of capabilities (Weinberg et al., 
1989; Luebeck et al, 2002; Renehan et al., 2007).  
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Hanahan and Weinberg (Hanahan and Weinberg, 2000) postulated that 
there are six “hallmarks of cancer”. Firstly, tumour cells acquire the capability 
of self sufficiency in growth signals. This would inherently bring the cell to a 
constant proliferative state. Secondly, the tumour cells develop insensitivity to 
antigrowth signals. Thirdly, tumour cells suppress anti-proliferative signals. 
Fourthly, the acquired resistance toward programmed cell death to evade 
apoptosis allows tumour cells to survive and continue their growth. The fifth 
hallmark is when tumour cells become immortalized through sustaining of 
angiogenesis. Lastly, the final stage of tumour progression involves tissue 
invasion and metastasis, which is the major cause of cancer-related deaths.  
 
In summary, Hanahan and Weinberg suggested that the six cellular 
processes are essential for the transformation of a normal cell into a tumour 
(Hanahan and Weinberg, 2000). However, a recent sequence evaluation of 
colon and breast cancer genomes suggested that the number of altered cellular 
processes required for tumourigenesis might be even higher (Sjoblom et al., 
2006). Evidently, genetic instability events are the key factors in affecting 
essential cell cycle activities leading to tumorigenic consequences (Hanahan 







1.3 Molecular Mechanisms of Colorectal Cancer Development 
 
The first attempt to describe the development of colorectal cancers was done 
by Fearon and Vogelstein in 1990. They described a traditional pathway that 
incorporated a series of cumulative genetic aberrations that occurred in 
parallel to the transition from adenoma to adenocarcinoma (Figure 1). Since 
then, researchers have come to understand that colorectal cancer is a complex 
disease. As a result of their heterogeneity, there are at least three major 
molecular pathways to colorectal cancer (Worthley and Leggett, 2010). These 
include the predominant chromosomal instability (CIN) pathway that is 
accountable for the majority of colorectal cancers (Figure 2). The other major 
pathway to sporadic colorectal cancers is the CpG island methylator 
phenotype (CIMP), which includes the sporadic microsatellite instability 
(MSI) high cancers (Figure 2). Finally, there is the pure MSI pathway 
resulting from germline mutation in a DNA mismatch repair (MMR) gene. 
Hereditary nonpolyposis colorectal cancer (HNPCC) development occurs 





Figure 1. The genetic model of colon cancer development. The figure above 
shows the multistep progression of colon cancer from a normal cell to a 




Figure 2. A simplified working model of sporadic colorectal tumour 
development incorporating the CIN and CIMP pathways. This diagram 
shows that genetic instability is critical in the transition from a normal cell to 
an adenocarcinoma. This diagram is adapted and reproduced with permission 
from the review paper by Worthley and Leggett (Worthley and Leggett, 2010). 
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1.3.1 The Chromosomal Instability (CIN) Pathway 
 
The majority of all colorectal cancers (approximately 70% to 85%) 
develop via the CIN pathway (Grady, 2004). As it precedes the development 
of a polyp, the dysplastic aberrant crypt focus (ACF) is the earliest form of  
lesion identifiable from this pathway (Takayama et al., 2006). In this pathway, 
molecular aberrations are accumulated in significant part through 
chromosomal abnormalities (aneuploidy). The CIN pathway is associated with 
mutations in the APC gene and the KRAS oncogene (Grady, 2004). 
Additionally, the CIN pathway also involved the loss of chromosome 5q 
(which contains the APC gene), loss of chromosome 18q and deletion of 
chromosome 17p (which contains the important tumour suppressor gene TP53 
gene) (Grady, 2004).  
 
The binding of APC to β-catenin helps to suppress the Wnt-signaling 
pathway (Cadigan and Liu, 2006). The Wnt signalling regulates growth, 
apoptosis and differentiation (Kuhnert et al., 2004). Hence, the APC gene 
plays an important tumour suppressor role in the CIN pathway. The frequency 
of APC or β-catenin mutation in early adenomas has been reported to be as 
high as 80% (Takayama et al., 2006). Mutation of APC is found in 
approximately 60% of colonic and 82% of rectal cancers (Takayama et al., 
2006). Another important gene within the CIN pathway is the KRAS gene. 
Abnormal KRAS gene can interrupts the constitutive signalling through the 
downstream, RASRAF- MEK-ERK pathway (Leslie et al., 2002). In this 
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cascade, BRAF, which is also relevant in the CIMP pathway, is another 
important factor (Leslie et al., 2002). This suggests that the role of KRAS is 
not unique to the CIN pathway (Worthley and Leggett, 2010). Activating 
KRAS mutations are found in 35–42% of colorectal cancers (Leslie et al., 
2002). The allelic loss at 18q site is found in up to 60% of colorectal cancers. 
DCC, SMAD2 and SMAD4 are all located at chromosome 18q. In particular, 
SMAD2 and SMAD4 are involved in the TGF-β signalling pathway, which is 
important in growth regulation and apoptosis (Woodford-Richens et al., 2001). 
The allelic loss of chromosome 17p results in the impairment of TP53 (Leslie 
et al., 2002). This loss is often considered as a late event in the traditional 
pathway (Worthley and Leggett, 2010). The normal p53 protein has several 
functional roles - to increase the expression of cell-cycle genes, to slow the 
cell cycle and provide sufficient time for DNA repair. Moreover, p53 also 
induces pro-apoptotic genes, thus containing the genetic insult through 
programmed cell death. Due to these important functional roles, the loss of 
normal p53 functions is evident in the factor that P53 abnormalities increase 
relative to the advancing histological stage of the lesion being studied 
(Worthley and Leggett, 2010). This is observed in 4% to 26% of adenomas, 
50% of adenomas with invasive foci and 50% to 75% of colorectal 




1.3.2 The CpG Island Methylator Phenotype (CIMP) Pathway 
 
The CIMP pathway is accountable for 15% of sporadic cases (Jass, 2005). The 
CIMP pathway provides the epigenetic instability necessary for sporadic 
cancers to inactivate the expression of key tumour suppressor genes such as 
MLH1. A panel of CpG island methylation markers on the basis of certain 
thresholds currently defines CIMP-positive colorectal cancers (Weisenberger, 
2006).  
 
CIMP-positive colorectal cancers are characterised by a well-defined 
cluster of colorectal cancers originating from the proximal location 
(Weisenberger, 2006). Interestingly, older women also have a tendency for the 
development of CIMP (Weisenberger, 2006). CIMP-positive colorectal 
cancers that are MSI-H share MSI-H characteristics in having relatively good 
prognosis (Weisenberger, 2006). However, in the absence of MSI-H, the 
CIMP-positive phenotype has poorer prognosis, as the same time, 
characterized by more advance pathology (Weisenberger, 2006). CIMP-
positive colorectal cancers also differ from the other pathways with respect to 
their precursor lesion (Shen et al., 2007). Colorectal cancers developing via 
the CIN pathway, and also in HNPCC, originate from adenomatous polyps 
(Shen et al., 2007). However, sessile serrated adenomas are the chief 




1.3.3 The Microsatellites Instability (MSI) Pathway 
 
Microsatellites are nucleotide repeat sequences scattered throughout the 
genome and MSI refers to a discrepancy in the number of nucleotide repeats 
found within these microsatellite regions in tumour versus germline DNA 
(Boland et al., 1998). The MSI is the result of mismatch repair (MMR) 
dysfunction. The MMR system is composed of at least seven proteins 
including, MLH1 and MSH2. The MLH1 and MSH2 protein are essential in 
the mismatch repair machinery and mutations in MLH1 and MSH2 have been 
implicated in HNPCC (Boland et al., 1998). 
 
Many colorectal cancers with an intact MMR system will still possess 
frameshift mutations at a small number of microsatellites (Boland et al., 
1998). Therefore, a standardised panel of microsatellites was devised to 
provide uniformity of definition for research and practice (Worthley and 
Leggett, 2010). The currently endorsed panel includes two mononucleotide 
(BAT25 and BAT26) and three dinucleotide microsatellites (D5S346, 
D2S123, and D17S250) (Worthley and Leggett, 2010). Considerable MSI or 
MSI-high (MSI-H) is defined as MSI at ≥2 (40%) of the five specified sites, 
MSI-low (MSI-l) as MSI at one site, and microsatellite stable (MSS) when no 
instability is demonstrated at these markers (Worthley and Leggett, 2010). 
Studies have also shown that BAT26 alone is sufficient for measure of 
microsatellite instability in tumours (Samowitz et al., 2005b; Bacani et al., 
2005). MSI leads to a dramatic increase in genetic errors and several 
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microsatellites are present in genes implicated in colorectal carcinogenesis, 






1.4 Implications of Cancer Stem Cells 
 
The repeated identification of mutated genes, specifically the oncogenes and 
tumour suppressor genes, reinforces the idea that such mutations can program 
the development of human cancer subtypes (Frattini et al., 2004). However, it 
is becoming increasingly difficult for researchers to reconcile with the opinion 
that the sole targets for most cancer transformations are the differentiated 
cells. This is due to the minute probability that an individual differentiated 
epithelial cell will accumulate enough mutations to create a tumour. Recently, 
a number of studies postulated that human cancer could be considered as a 
stem cell disease. These studies suggest that many signalling pathways 
involved in the maintenance of normal stem cells are mutated in human 
cancers – these include WNT, beta-catenin, TGF-beta and PTEN (Crowe et 
al., 2004; Woodward et al., 2005; Miller et al., 2005).  
 
According to the cancer stem-cell concept, tumours are not merely simple 
monoclonal expansions of transformed cells, but complex tissues where 
 13 
abnormal growth is driven by a minority of cancer stem cells (Boman and 
Huang, 2008a). These cancer stem cells have acquired tumour-related 
“hallmarks” such as uncontrolled growth and the ability to form metastases 
while maintaining its inherent capacity to self-renew and differentiate 
(Dalerba et al., 2007; Boman and Huang, 2008a; Boman et al., 2008b). Polyak 
and Hahn (Polyak and Hahn, 2006) describe the process of malignant 
transformation involving stem cells (Figure 3). The first step is that the tumour 
is initiated by a single mutation that disrupts the regulated asymmetric division 
in stem cells. The mutated “cancer” stem cells then differentiate into other 
committed “cancer” daughter cells. This “cancer” daughter cell harbours a 
combination of other mutations that can reprogram the malignant state. 
Eventually a tumour is initiated by mutations in the committed “cancer” 
daughter cells through an epithelial-mesenchymal transition. This hypothesis 
is supported by the following experimental observations in human acute 
myeloid leukaemia (Lapidot et al., 1994). The first observation is that a 
minority of cancer cells within each tumour possess tumourigenic potential 
when transplanted into immunodeficient mice (Ricci-Vitiani et al., 2007). 
Secondly, tumourigenic cancer cells are distinguished by a characteristic 
profile of surface markers. This profile can be reproducibly isolated from non-
tumourigenic cells through by flow cytometry (Ricci-Vitiani et al., 2007). 
Lastly, tumours grown in-vitro exhibited similar phenotypic heterogeneity of 
the parent tumour - containing mixed populations of both tumourigenic and 
non-tumourigenic cancer cells (Ricci-Vitiani et al., 2007). Subsequently, these 
observations are also extended to human solid tumours. Cancer cell 
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subpopulations have been identified from different human solid cancers, such 
as brain (Ogden et al., 2008; Johannessen et al., 2009), ovarian (Ferrandina et 
al., 2008), colon (Ricci-Vitiani et al., 2007; Horst et al., 2009a; Horst et al., 




Figure 3. A simplified model of malignant transformation based on the 
cancer stem cell concept. This model describes the transformation of a 
tumour cell from a normal cell as proposed by Polyak and Han (Polyak and 
Han, 2006). The figure above illustrates the schematic organization of a 
normal epithelial cell including stem cells and their niche (A). A tumour is 
initiated upon a mutation (B). These mutated cancer stem cells disrupt normal 
asymmetric division and differentiate into committed daughter cells (C). The 
daughter cells eventually form a fully transformed cell by accruing other 
mutations (D). 
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 1.5 The Prognostic and Predictive Markers Examined in this Study 
 
A biomarker is a biological entity that provides indications of the 
physiological state of a cell (Srinivas et al., 2001). Hence biomarkers could 
serve as prior indicators of warning for disease progression and can potentially 
predict receptivity to clinical treatment. A predictive marker is a factor that 
indicates sensitivity or resistance to a specific treatment. These markers are 
particularly important in the treatment of cancers, as different cancers have 
varied response to anti-cancer therapies. Prognostic markers, on the other hand 
provide information on survival outcome independent of chemotherapy 
administered. 
 
 The gold standard of prognostic markers in colorectal cancer is the 
AJCC TNM stage (Table 1), but this current staging method is insufficient 
especially in stage II and III disease. This is due to the wide variation in 
recurrences rates (Table 2). Hence, there is a need for development of novel 
prognostic and predictive markers that focus on individualized approach to the 
cancer treatment. Apart from surgical resection, current forms of treatment for 
colorectal cancers involve several chemotherapeutic agents administered to 
colorectal cancer patients. In the last fifteen years, the most commonly used 
chemotherapeutic agent used is 5-Fluorouracil (5-FU). 5-FU metabolises to a 
number of active metabolites such as 5-fluoro-deoxyuridine monophosphate 
and 2-deoxy-5-fluoridine. The principal target of 5-FU is thymidylate synthase 
(TYMS) – a key enzyme involved in purine nucleotide synthesis (Kundu et 
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al., 1974). 5-FU works by inhibiting TYMS that causes depletion of 
thymidines and disruption DNA and RNA synthesis. As a result, the cell 
undergoes apoptosis by “thymineless” death. Interestingly, part of the interest 
in the cancer stem-cell concept comes from the notion that current therapies 
are not effectively targeting such populations. Polyak and Han (Polyak and  
Han, 2006) postulate that this is due to the fact that current therapies are 
targeting rapidly proliferative cells, which are usually “amplifying” cells in the 
transitory state between normalcy and malignancy. This idea would explain 
the high rate of therapeutic failures and cancer recurrence. 
 
Hence, many clinicians have taken another approach by using a 
“surrogate” marker to determine response for chemotherapeutic agents as well 
as survival benefits (Willett et al., 2005). A number of markers have been 
identified for various chemotherapeutic agents over the past few decades 
(O’Connell et al., 1992; McLeod and Murray, 1999; Allegra et al., 2003; 
Dietmaier et al, 2006). However, none of these biomarkers are fully predictive 
or informative. These could be due to the complex mechanisms involved in 
cancer progression, as well as resistance to treatment (Duffaud and Therasse, 
2000). With the current awareness of the cancer stem-cell concept, it is of 
importance to examine the prognostic and predictive effects of these cancer 
stem-cell markers in colorectal cancers. Currently, there are limited data to 
support the clinical relevance of cancer stem cells. Taking into consideration 
that the working mechanisms of the cancer stem-cell concept may incorporate 
many molecular pathways (Barozzi et al., 2002), we have examined a panel of 
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known biomarkers and cancer stem-cell markers in relation to their predictive 
and prognostic value in colorectal cancer patients in this study. The 
subsequent subsections will briefly review the key biomarkers utilized in this 




1.5.1 p53  
 
The p53 tumour marker encodes for a 53kDa phosphoprotein (Cobbers et al., 
1998). It is inactivated in many tumour types (Kirsch and Kastan, 1998). 
These include point mutations, small deletions and insertions that lead to total 
or partial inactivation of the protein functions (Soong et al., 2000; Iacopetta et 
al., 2006). The inactivation of TP53 gene is postulated to eradicate its ability 
for genomic maintenance – through regulation of cell cycle arrest, DNA repair 
mechanisms and cell apoptosis (Soong et al., 2000). In breast cancer, the 
mutation of TP53 is consistently associated with poorer survival outcomes 
(Pharoah et al., 1999). Although well studied in colorectal cancers, there has 
been a lack of consensus regarding the prognostic significance of p53 protein 
expression (Pharoah et al., 1999). This could be due to the choice of 
methodologies involved - different mono- or polyclonal immunohistochemical 
antibodies, fresh tissue samples or archival material have been used in various 
studies. Moreover, there is a lack of general agreement on the interpretation of 
positive expression - the number of cells that need to be stained for a tumor to 
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be considered positive for p53 overexpression. Additionally, TP53 gene 
mutations may possess different prognostic value dependent on the site of 
tumour origin as well as chemotherapy treatment status of the patients (Russo 
et al., 2005). 
  
 The relationship between p53 protein expression and response to 
chemotherapy in human cancers is unclear. However, evidence for a link 
between dysfunctional TP53 gene and failure to respond to therapy has been 
found in mice. For example, p53-null mice have been found to be resistant to 
apoptosis induced by 5-FU in cancers of the small intestine (El-Deiry, 2003). 
 
 
1.5.2 Cyclooxygenase 2 (COX-2) 
 
COX-2 is an enzyme responsible for the synthesis of the prostanoids during 
inflammatory response (Laird, 2005). The expression of COX-2 was shown in 
70% to 80% of colorectal cancer cases. Hence it was believed to play an 
important role in colorectal cancer development (Soumaoro et al., 2004; Fux 
et al., 2005). Similar to TP53 mutation, the role of COX-2 as a prognostic 
indicator has conflicting results from various studies (Soumaoro et al., 2004; 
Fux et al., 2005). Moreover, COX-2 expression was shown to be regulated by 
p53 (Subbaramaiah et al., 1999). This suggested that TP53 mutation might 
exhibit a de-regulative effect on COX-2 expression (Subbaramaiah et al., 
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1999). Recently, COX-2 specific inhibitor, celecoxib, was demonstrated to 
inhibit colorectal cancer cells growth in-vitro (Lev-Ari et al., 2005).  
  
 A number of studies have reported that higher COX-2 expression in 
colorectal cancer was significantly associated with more advanced disease and 
pathological variables (Sheenhan et al., 1999; Masunaga et al., 2000). Patients 
having positive COX-2 tumours survived for a shorter time than those with 
negative COX-2. It is widely considered that tumour invasiveness, frequent 
metastasis, and expression in larger tumours are responsible for the worse 
prognosis for patients with COX-2-positive tumours. COX-2 overexpression is 
also reported to be strong predictor of chemotherapy response in locally 
advanced cervical cancer patients (Ferrandina et al., 2002). COX-2 has been 
demonstrated to induce Bcl-2 protein and to be associated with 
neoangiogenesis in tumour-bearing mice. As both inhibition of apoptosis and 
promotion of neoangiogenesis are related to chemotherapy resistance (Cooper 
et al., 1998), it has been postulated that COX-2 expression could play a role as 





The p27 gene is a 198 amino acid protein (Ponce-Castaneda et al., 1995). It is 
a cyclin-dependent kinase inhibitor that regulates progression of cells from G1 
into S phase in the cell cycle. Increased expression of p27 in mammalian cells 
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induces a G1 block of the cell cycle (Hengst et al., 1996). The high expression 
levels of p27 found in quiescent cells suggest that the p27 gene also plays a 
role in maintaining cells in G0 (Hengst et al., 1996). As p27 has a nuclear 
localization signal in its -COOH terminus, loss of p27 expression may result in 
the development or progression of tumours. As such, p27 is being increasingly 
recognized as an important factor for determining the biological behaviour of 
invasive tumours as demonstrated by the evidence of increased body size and 
spontaneous tumour formation in animal models lacking p27 expression 
(Polyak et al, 1994; Nakayama et al., 1996; Ponce-Castaneda et al., 1999). It 
is therefore not surprising that p27 has been implicated in many human 
cancers, including colorectal cancers (Guo et al., 1997; Mori et al., 1997). 
Variable levels of p27 expression have been observed in benign and malignant 
epithelial components of the colorectum (Loda et al., 1997). Several studies 
reported that the lack of p27 expression was associated with short patient 
survival (Belluco et al., 1999; Yao et al., 2000; Rossi et al., 2002). In some 
studies, it was suggested that p27 expression was an independent predictor of 
survival for patients specifically with early stage colorectal cancers (Zhang et 
al., 2001) whereas, studies by Tenjo et al. (2000) observed that p27 expression 
as an independent prognostic marker for patients with stage III colorectal 
cancers.  
 
 Interestingly, there have not been many studies reporting on the 
predictive value of p27 expression in colorectal cancers. Currently, there is 
only a single report from a large prospective randomized trial in colon cancer 
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(Kobayashi et al., 2002). In this study, analysis of 500 stage III colorectal 
cancers showed reduced p27 expression predicted longer time to recurrence 
after adjuvant chemotherapy regimes.  
 
 
1.5.4 CD133  
 
CD133 (also known as Prominin-1 or AC133), a transmembrane pentaspan 
protein, was initially described as a surface antigen specific to human 
haematopoietic stem cells (Horst et al., 2008). It is commonly regarded as a 
marker for murine neuroepithelial cells and several other embryonic epithelia. 
Although the biological function of the CD133 gene remains unknown, 
CD133 has increasingly been recognized as a stem cell marker for normal and 
cancerous tissues. The expression of CD133 is currently being used for the 
isolation of stem cells from numerous tumours, including colorectal tumours. 
Additionally, the prognostic value of CD133 has been well studied in various 
cancers. In pancreas cancer, CD133 expression was closely related to poor 
prognosis and was an independent prognostic indicator. Maeda et al. (Maeda 
et al., 2008) reported the five-year survival rate of CD133-positive patients 
with pancreatic cancer was significantly lower than that of CD133-negative 
patients, and CD133 expression was an independent prognostic factor by 
multivariate analysis. In liver cancer, Song et al. (Song et al., 2008) reported 
that positive CD133 expression correlated with increased tumour grade, 
advanced disease stage and elevated serum alpha-fetoprotein levels.  
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CD133 expression has also been linked to chemoresistance (Liu et al., 
2006; Ma et al., 2008). In vitro studies have shown that CD133+ cells are 
more resistant to radiochemotherapy than CD133− tumour cells in breast 
cancer and glioma. CD133+ hepatocellular carcinoma and glioblastoma cell 
lines show increased expression of BCRP1, a putative drug resistance protein 
(Liu et al., 2006; Smith et al., 2008). The phosphorylation of Akt and 
subsequent accumulation of anti-apoptotic signals in Akt/PKB survival 
pathways have also been suggested to contribute to the chemoresistance of 
CD133+ tumour cells (Ma et al., 2008). The CD133+ cell population in 
colonic cancer has been described as chemotherapy resistant after 
xenotransplantation in severe combined immunodeficient (NOD/SCID) mice. 
However, there has not been any conclusive study linking CD133 expression 





The protein SOX-2 is a transcription factor from the highly conserved family 
of high-mobility group box factors (Kim et al., 2008). They are important 
functionally as regulators of embryonic development and determinants of cell 
fate (Kim et al.., 2008; Schoenhals et al., 2009). Together with OCT-4, SOX-2 
plays a crucial role in regulating expression of lineage commitment factors 
(Saigusa et al., 2009). 
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Expression of SOX-2 has been shown to be confined to the fundic and 
pyloric regions of the stomach and undetectable from the duodenum though to 
the rectum (Tsukamoto et al., 2005). It has also been reported that SOX-2 are 
expressed at considerably lower levels in both the mixed gastric and intestinal-
type and solely intestinal-type of gastric cancers (Li et al., 2004). 
Interestingly, poorly differentiated or undifferentiated tumours share 
phenotypic traits similar to that of undifferentiated embryonic cells. These 
observations suggest that SOX2 may also play a role in metaplastic 
differentiation in a similar manner that it is regulating embryonic stem cells 
development. This is in agreement with the hypothesis that embryonic genes 
are reactivated in tumour cells. A recent study has associated SOX-2 with 
poorer prognosis in gastric cancer (Otsubo et al., 2008). In this study, patients 
with advanced cancers showing SOX-2 methylation had a significantly shorter 
survival time than those without. Additionally, SOX-2 was strongly expressed 
in serrated polyps, mucinous and signet ring cell carcinomas (Park et al., 2008. 





Similar to SOX-2, OCT-4 is also a transcription factor that plays an important 
role in maintaining embryonic stell-cell potency (Saigusa et al., 2009). 
Expression of OCT-4 mRNA is commonly observed in totipotent and 
pluripotent stem cells of pre-gastrulation embryos (Nichols et al., 1998). In 
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OCT-4 knock out mice, the animals exhibit early lethality due to the lack of 
inner cell mass formation. This suggests the OCT-4 gene has a functional role 
for self-renewal of embryonic stem cells (Nichols et al., 1998). Studies have 
also indicated that the OCT-4 gene is necessary for survival of early 
primordial germ cells (Hattab et al., 2005). Apart from expression in germ 
cells, OCT-4 protein is also expressed in germ cell tumours such as 
germinoma (Jones et al., 2004a), seminoma and embryonic carcinoma (Jones 
et al., 2004b). Ectopic OCT-4 expression in somatic stem cells has also been 
shown to cause epithelial dysplasia and is associated with tumour formation 
(Hochedlinger et al., 2005). More recently, several studies have described the 
presence of OCT-4 in many solid tumour types in breast (Ezeh et al., 2005), 
pancreatic (Iki et al., 2006) and bladder (Atlasi et al., 2007) cancers. Despite 
these developments, the prognostic and predictive effect of OCT-4 in 
colorectal cancers is still unknown. 
 
 
1.6 Advanced Histopathological Techniques Employed in this Study 
 
Rapid developments have been made in identifying predictive and prognostic 
markers in colorectal cancers.  A large part of this is due to the improvements 
in computing technologies which have made possible the simultaneous 
analysis on a large number of genes or proteins in a large cohort of patients. At 
the same time, the advancements in pathological analytical instruments also 
provide us an opportunity to made use of the repository of formalin-fixed 
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paraffin-embedded tissue materials within our hospital. The subsequent 
sections will describe some of the resources and histopathological techniques 
we have employed in this study. 
 
 
1.6.1 Archival Pathological Specimens and Tissue Microarray Techniques 
 
Formalin-fixed paraffin-embedded tissue collections represent a vast resource 
of biomaterials available for retrospection biomedical research. This resource 
is not as popularly utilized due to several limitations. They are the difficulties 
in DNA extraction and DNA amplification due to the cross-linkage damages 
in the DNA caused by the fixation process (Cao et al., 2003), as well as 
incomplete cataloguing of patients’ clinical-pathological information. 
Throughout the last decade, researchers have modified DNA extraction 
procedures in formalin -fixed paraffin embedded tissues, such as longer 
incubation times and increased alkalinity of the buffer solution, to improve the 
DNA yield (Coombs et al., 1999; Jalouli et al., 1999; Fang et al., 2002). 
Moreover, several commercial entities have produced “kits” just for extraction 
of DNA from formalin -fixed paraffin embedded tissues, thereby standardizing 
protocols. In addition, the improvements made in polymerase chain reaction 
technologies have also made it possible for shorter segments of DNA to be 
amplified. Hence, researchers are no longer restricted by the unavailability of 
DNA extracted from formalin -fixed paraffin embedded tissues. 
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Apart from extracting DNA, formalin -fixed paraffin embedded tissues 
also allows for immunohistochemistry experiments to be performed. However, 
this could be tedious and time-consuming if there are a large number of 
formalin -fixed paraffin embedded tissues blocks to be evaluated. In order to 
examine the immunohistochemical expression in a more streamlined manner, 
the tissue microarray (TMA) technology facilitates the analysis of larger 
number of formalin-fixed paraffin embedded tissues materials with minimal 
effort. This technology works on the principle of incorporating multiple donor 
tumours within a single recipient block in a systematic manner. Through 
haematoxylin and eosin staining, the TMA allows for characterization of many 
tumour tissues simultaneously (Salto-Tellez et al, 2007). In addition, protein 
expression can also be examined using sections from the tissue microarray 
blocks by immunohistochemistry. Moreover gene amplification studies can 
also be conducted using the TMA sections for DNA and RNA in situ 
hybridization techniques. Apart from allowing tremendous savings in analysis 
time, labour and reagent costs, this technology also significantly accelerates 
biomarker studies examining associations between molecular changes and 
clinical endpoints (Kononen et al., 1998; Torhorst et al., 2001). The TMA 
technology, when used in tandem with automated immunohistochemical 
stainers and pathological scoring machines, offers an integrated solution for 
high-throughput work thereby minimizing the amount of time required for the 




1.6.2 Automated Imaging and Pathological Scoring Platform 
 
The technological advances in computing hardware and software have 
immensely affected every scientific field, including the area of pathology. The 
quest for improving pathological scoring systems and at same time reducing 
the amount of time taken for pathological scoring has led to the innovation of 
computer-assisted scoring techniques. Indeed, the use of automated systems in 
pathology has become more common in the histology laboratory. Recent 
studies have also suggested that automated systems may be more sensitive and 
objective than manual methods (Mofidi et al., 2003). 
 
Automated or computer-assisted analysis of immunostaining removes 
the subjectivity that is inherent with the commonly used practice of estimation 
by visual inspection. The integration of computerized image scanning and 
analysis in these computer-assisted systems also represent a reproducible 
method of analyzing immunostains. An added advantage of computer assisted 
scoring is the ability to assign continuous values. Traditionally, these scorings 
are usually available as “categorical” values for statistical analysis (Walker et 
al., 2006). Having the values scoring as a continuous variable allow for more 
sensitive statistical analysis. As computer-aided measurements are not 
subjected to external factors such as human fatigue, ambient lighting or noise, 
other possible benefits of using a computer-assisted platform include 
reproducibility and reliability of the scoring results. Additionally, computer-
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assisted pathological scoring may cut down on the timing factor as it can be 
programmed to run without any human supervision. 
 
 
1.7 Aims of Study 
 
The aims of this study, as summarized in the study workflow illustrated in 
Figure 4, were to resolve both biological and methodological aspects of our 
hypothesis in determining clinical significance of cancer stem-cell marks in 
colorectal cancer. 
 
Our main objective is to understand the clinical value of cancer stem-cell 
markers and their relationship with other key genes and pathways related to 
colorectal cancer development. In particular, we intend to: 
(i) study the prognostic and predictive effect of cancer stem cell 
markers in colorectal cancers 
(ii) examine the associations of cancer stem cell markers with KRAS 
and BRAF mutations as well as microsatellite instability 
 
In order to achieve aims (i) and (ii), we had to establish a robust 
methodology adapted to the challenging conditions of storing formalin-fixed 
paraffin-embedded tissue blocks in the tropical climate. Therefore, we also 
have to: 
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(iii) determine if DNA and immunochemical antigenic sites are 
preserved in formalin-fixed paraffin-embedded tissues of primary 
colon carcinomas 
(iv) evaluate the level of concordance of an automated imaging and 




Figure 4. Schematic representation of the study workflow. 
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2.1.1 Samples for Examining Availability of DNA and 
Immunohistochemical Antigenic Sites from Archival Formalin-Fixed 
Paraffin-Embedded Tissues 
 
To examine if DNA and immunohistochemical antigenic sites are available 
from archive formalin-fixed paraffin-embedded tissues stored in the tropical 
climate of Singapore, we utilized samples from a legacy collection of 
formalin-fixed paraffin-embedded tissue blocks. This legacy collection is a 
single repository of formalin-fixed paraffin-embedded materials collected at 
the General Hospital of Singapore, during a time when only a single Pathology 
Department existed in Singapore. Currently, the legacy collection is a resource 
administered by the Singapore General Hospital and National University 
Hospital.  
 
A total of 90 archival formalin-fixed paraffin-embedded tissues from 
1959 to 1984 were obtained from the legacy collection. As the blocks 
followed a specific numbering format (first 2 digit denoting year, followed by 
5 digit case identification number), these blocks of various tumour types were 
randomly selected using SPSS random number generator. The mean age for 
these formalin-fixed paraffin-embedded tissues was 34.5 (range 22 to 47 years 
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of age from time of tissue fixation).  The formalin constitutions and durations 
used to fix these tissues were unknown due to lack of standardization during 
that period. The corresponding pathological reports were available. Further 
verification of the block-report pairing concordance was done after examining 
the haemotoxylin and eosin stained slide.  
 
 
2.1.2 Samples for Studying Prognostic and Predictive Significance of 
Cancer Stem-Cell Markers 
 
For the study of the prognostic and predictive significance of the cancer stem-
cell markers, a cohort of 501 consecutive colorectal cancer cases treated by 
surgical resection at the National University Hospital of Singapore between 
1990 and 1999 inclusive. The available clinical-pathological information 
included gender, age, tumour size, tumour stage, histological grade, vascular 
invasion, perineural invasion, lymphatic invasion and cancer-specific survival 
time (Table 3). Clinicopathological data was documented at the initial 
diagnosis and during subsequent follow-up. Staging was based on pathological 























































   
Gender   
Male 240 48 
Female 261 52 
   
Age   
< 60 177 35 
≥ 60 324 65 
   
Ethnicity   
Chinese 422 84 
Non-Chinese 79 16 
   
Histological grade   
Well differentiated 17 3 
Moderately differentiated 429 86 
Poorly differentiated 55 11 
   
Tumour stage   
I and II 231 46 
III and IV 270 54 
   
Tumour site   
Rectal 111 22 
Colon 390 78 
   
Tumour size   
< 5cm 306 61 
≥ 5cm 195 39 
   
Lymphatic invasion   
Negative 461 92 
Positive 40 8 
   
Perineural invasion   
Negative 478 95 
Positive 23 5 
   
Vascular invasion   
Negative 451 90 




Cases treated with chemotherapy underwent intravenous injection with 5-FU 
using the Mayo regimen. One complete cycle of treatment involved dosage 
administration ranging from 500 to 900 mg/m2/day for 3 to 5 consecutive 
days. Each cycle was repeated monthly for 6 months or until progression of 
disease, patient refusal or adverse reactions to the treatment.Tumour response 
to treatment was classified according to the standard World’s Health 
Organisation response criteria. 
 
 
2.1.3 Samples for Studying the Implications of Cancer Stem-Cell Markers 
with KRAS, BRAF and Microsatellite Instability 
 
A subset of 117 cases from the 501 cases (described in the previous 
subsection) was utilized for the study of the associations of cancer stem-cell 
markers with KRAS, BRAF and microsatellite instability. These 117 cases 
were selected based on their advanced staging status (stages III and IV). 
 
 
2.1.4 Approval from Ethic’s Committee 
 
Prior approvals from the ethic’s committee of the National Healthcare Group 
and the National University of Singapore were obtained before 
commencement of the research.  
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The approval for the work on cancer stem-cell markers and its 
correlation with other immunohistochemical biomarkers and 
KRAS/BRAF/microsatellite instability status was obtained from the ethic’s 
committee of the National Healthcare Group (DSRB Domain B/09/284). The 
work on comparing the concordance of human pathological scoring and 
computer-assisted pathological scoring was approved by the ethic’s committee 
of the National Healthcare Group (DSRP Domain B/09/116). The ethic’s 
committee of the National University of Singapore (NUS-IRB05-017) 
approved the general working protocols for immunohistochemistry, TMA 





2.2.1 Tissue Microarray Construction 
 
For the study of the prognostic and predictive significance of the cancer stem-
cell markers, formalin-fixed, paraffin-embedded colorectal cancer tissue 
samples were retrieved from the tissue repository of the Department of 
Pathology.  The samples were arrayed as the previously reported method from 
our laboratory (Salto-Tellez et al., 2007; Das et al., 2008). Briefly, a 
haematoxylin and eosin–stained section was prepared from each selected 
tissue block. This was read under the supervision of a trained pathologist to 
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define the representative tumour regions for subsequent arraying. The 
designated zone of each donor block was punched with a 0.6mm diameter 
tissue cylinder. The punched sample was then deposited into a recipient block 
using a tissue-arraying instrument (Chemicon, USA).  
 
The blocks were arrayed chronologically by the years the samples were fixed 
and embedded. The tumour and normal cores were separated into two different 
blocks but sharing the same layout for comparisons. After construction of the 
tissue microarray blocks, multiple 4 microns sections were cut consecutively 
using a Leica RM2255 (Leica, Germany) microtome until all of the tissue 
samples were represented on single sections. These sections were separately 
placed on charged Matsunami (Matsunami Glass Ltd, Japan) polylysine-
coated slides for immunohistochemistry staining. 
 
Prior to the construction of this TMA, a preliminary set of TMA incorporating 
the 90 samples (mentioned in Section 2.1.1) were constructed to assess the 




2.2.2 DNA Extraction 
 
In order to optimise DNA extraction from formalin-fixed paraffin-embedded 
colonic tissue to generate DNA suitable for polymerase chain reaction, we 
conducted a preliminary test to compare different methods of DNA 
extractions. These methods included comparisons between two different 
commercial kits (Qiagen DNeasy and Gentra Puregene) and a laboratory-
developed Proteinase-K based DNA extraction method. For this test, ten 
paraffin blocks were randomly selected from the set of 90 blocks collated from 
the legacy collection. Sections of 10 microns in thickness were cut from each 
block. A new sterile blade was used for each block to avoid contamination 
among the samples. The experiment was conducted in triplicates. 
 
 For the Qiagen commercial kit, DNA was extracted using their 
DNeasy kit (Qiagen, USA) according to the manufacturer’s protocol. The 
tissues were dewaxed with xylene, followed by two washes with 100% ethanol 
twice to remove residual xylene. After dewaxing, tissues were digested 
overnight at 56°C with 180µl of ATL buffer and 20µl proteinase K. After 
digestion, 200 µl of AL buffer was added and incubated at 70°C for 10 
minutes, followed by ethanol precipitation. The solution was transferred into a 
spin column, and washed with the wash buffers provided in the kit. DNA was 
eluted with 200 µl of AE buffer.  
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For the Gentra commercial kit, DNA was extracted using their 
PureGene DNA extraction kit (Gentra Systems, USA). Briefly, the sections 
were dissolved in 600µl of histoclear and washed in absolute ethanol to 
remove excess histoclear, after which, each tube was added with 300ml of 
Puregene cell lysis solution and proteinase K (20mg/ml). Subsequently, they 
were incubated at 55ºC overnight until the cell lysate became clear. After 
cooling to room temperature, 100ml of protein precipitation solution was 
added and spin down at 13,200rpm for 5mins. The supernatant were decanted 
into a clean Eppendorf tube with 300ml of 100% isopropanol with 0.5µl of 
glycogen. They were then centrifuged at 13,200rpm to pellet the DNA. The 
DNA pellet was then washed with 70% ethanol and left to dry on a heat-block 
at 37ºC. The dried pellet was then re-suspended in DNA hydrating solution.  
 
 For the laboratory-developed method, the paraffinized sections were 
added with 500µl of 1M Tris EDTA. They were then incubated at 85ºC for 30 
minutes. The molten paraffin-tissue mixture was then placed immediately into 
an ice-bath and centrifuged at 10,000rpm at 4 ºC. After centrifugation, the 
solidified paraffin wax was removed. The remaining mixture was transferred 
to a new Eppendorf tube and 50µl of Proteinase K was added. The tube was 
then incubated at 37ºC overnight. 
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DNA quantifications were carried out using a Nanodrop ND-1000 
(Nanodrop Technologies, USA), which works on the principle of UV 




2.2.3 Assessment for Availability of DNA for Polymerase Chain Reactions 
 
Extracted DNA from the legacy collection was subjected to DNA 
amplification using the housekeeping gene β-actin. The primer sets were 
constructed to produce PCR products of various base-pair size. These primer 
sequences are summarized in Table 4. Amplification was set up in a 50ml 
reaction mixture containing one unit of PCR buffer, 1.5mM magnesium 
chloride, 200 µM dNTPs, 10pm of primers and 1.5 units of Taq polymerase. 
The PCR conditions were as follows: Initial denaturation at 95ºC for 3 
minutes, followed by 35 cycles of amplification at 94ºC for 30 seconds, 
annealing for 1 min at the respective annealing temperature and extension at 
72ºC for 1 min followed by an additional extension for 5 minutes at 72ºC. 
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5' gctccggcatgtgcaa 3' 
5' aggatcttcatgaggtagt 3' 
189 bp 
  
5' gtgggccgctctaggcaccaa 3' 
5' ctctttgatgtcacgcacgatttc 3' 
150 bp 
  
5' gatgagattggcatggcttt 3' 
5' caccttcaccgttccagttt 3' 
100 bp 
  
5' tccctggagaagagctacga 3' 
5' ggaaggaaggctggaagagt 3' 
98 bp 
  
5' cagctcctccctggagaaga 3' 





Table 5. Optimized concentrations and manufacturers for antibodies 
used. 
 




AE1/3 1:100 MNF116 Dakocytomation, Denmark 
CD133 1:10 AC133 Miltenyi Biotech, USA 
CD30 1:200 BER-H1 Dakocytomation, Denmark 
CD31 1:100 M89D3 BD Pharmingen, USA 
CD45 1:100 2H12 BD Pharmingen, USA 
CK20 1:500 KS20.8 Dakocytomation, Denmark 
CK7 1:500 OV-TL 12/30 Santa Cruz Biotech, USA 
COX-2 1:250 M-19 Santa Cruz Biotech, USA 
Ki67 1:200 MIB-1 Dakocytomation, Denmark 
OCT-4 1:1000 H-143 Santa Cruz Biotech, USA 
p27 1:500 SX53G8 Dakocytomation, Denmark 
p53 1:250 D-07 Dakocytomation, Denmark 
PCNA 1:1000 PC10 Dakocytomation, Denmark 
PSA 1:50 ER-PR8 Dakocytomation, Denmark 
S100 1:1000 S100-A1/1 Dakocytomation, Denmark 
SMA 1:1000 1A4 Dakocytomation, Denmark 
SOX-2 1:1000 57CT23.3.4 Abcam Inc, USA 
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2.2.4 KRAS Mutational Analysis 
 
KRAS mutations were determined by an allelic discrimination assay using the 
ABI 7900HT Sequence Detection System (Applied Biosystems, Foster City, 
CA). Briefly, genomic DNA was extracted from the formalin-fixed paraffin-
embedded tissues using the Gentra Puregene kit. The PCR reaction mix 
contained 5uL comprising 10ng of DNA, 1uL of TaqMan Universal PCR 
Master Mix (Applied Biosystems) and 5uL of primers. The forward primer 
sequence was 5'-AAGGTACTGGTGGAGTATTTG-3' and the reverse was 5'-
GTACTCATGAAAATGGTCAGAG-3'. The primer was designed to span 
codon 12 and 13 of KRAS exon 2. DNA was then submitted to the following 
cycle conditions: 95°C for 15 minutes; 40 cycles, 95°C for 15 seconds; and 
60°C for 1 minute. Data were analyzed with SDS2.0 software (Applied 
Biosystems). Each mutation detected by allelic discrimination was checked by 




2.2.5 BRAF Mutational Analysis 
 
Similar to the KRAS analysis, BRAF mutations were determined by an allelic 
discrimination assay using the ABI 7900HT Sequence Detection System 
(Applied Biosystems, Foster City, CA). Genomic DNA was extracted from the 
formalin-fixed paraffin-embedded tissues using the Gentra Puregene kit. The 
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PCR reaction mix contained 5uL comprising 10ng of DNA, 1uL of TaqMan 
Universal PCR Master Mix (Applied Biosystems) and 5uL of primers. The 
primer was designed to span the codon 600 (V600E) region of BRAF exon 15. 
The forward primer sequence was 5'- 
CTACTGTTTTCCTTTACTTACTACACCTCAG A3-3' and the reverse was 
5'- ATCCAGACAACTGTTCAAACTGATG -3'. DNA was then submitted to 
the following cycle conditions: 95°C for 15 minutes; 40 cycles, 95°C for 15 
seconds; and 60°C for 1 minute. Data were analyzed with SDS2.0 software 
(Applied Biosystems). Each mutation detected by allelic discrimination was 
checked by direct sequencing of the BRAF mutations located within codon 
600 of exon 15. 
 
 
2.2.6 Microsatellite Instability Analysis  
 
Standard microsatellite instability analysis was performed on paired tumour 
and normal tissue DNA samples using the microsatellite marker, BAT26. 
BAT26 alone was used as a general marker for microsatellite instability in this 
study. Studies have shown that this is sufficient for measure of microsatellite 
instability in tumours (Samowitz et al., 2005b; Bacani et al., 2005). Briefly, 
the fluorescent- labelled PCR products were mixed with a size standard 
(GeneScan 400HD ROX, Applera, Foster City, CA, USA), run on an 
automatic ABI3130 DNA analyzer, and evaluated with the GeneScan software 
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(Applera). A variation in number and size of peaks of a marker in tumour 





Sections were deparaffinised with three changes of histoclear, 2 minutes each, 
followed by rehydration in a series of graded ethanols (100%, 95% and 70%), 
a minute each, and lastly in a water bath for 2 minutes. 
 
Prior to incubation with primary antibody, the sections were subjected 
to various heat-induced epitope retrieval (HIER) pre-treatments, depending on 
the antibody of interest. The HIER was carried out with Dako pH6.0 citrate 
buffer (Dakocytomaton, Denmark) in a MicroMED TT Microwave Processor 
(Milestone Inc., Italy) for 5 minutes at 120oC. Following HIER pre-treatment, 
endogenous peroxidase activity in the tissue sections was blocked using Dako 
Peroxidase (Dakocytomaton, Denmark) for 10 minutes. This was followed by 
protein blocking using Dako Protein Block (Dakocytomaton, Denmark) for 30 
minutes. 
 
The dilution factors and incubation times of the primary antibodies 
used are listed in Table 5. The primary antibodies were diluted to the 
appropriate concentration with Dako antibody diluent (Dakocytomaton, 
Denmark). Various human tissues or cell lines embedded in paraffin with 
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known expression for the markers were used as positive controls. Negative 
controls consisted of the omission of primary antibody without any other 
changes to subsequent procedures.  
 
After incubation with the primary antibodies, detection of staining was 
carried out using an anti-mouse HRP-conjugated secondary antibody 
(Dakocytomaton, Denmark) at room temperature for 30 minutes. 
Chromogenic visualisation was then achieved by applying 3’3’-
diaminobenzidine (DAB)-substrate chromogen solution (Dakocytomaton, 
Denmark) for 5 minutes. The colour development was stopped by washing 
with distilled water. Subsequently, the sections were counterstained with 
Mille’s Modified Hematoxylin (Dakocytomaton, Denmark) for one minute. 
This was followed by a series of graded alcohols (70%, 95% and 100%) and 
histoclear. Finally, the stained sections were mounted with Matsunami clear 
coverslip (Matsunami Glass Ltd, Japan) using DPX mounting medium 
(Merck, Germany). 
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2.2.8 Pathological Scoring 
 
The immunohistochemical staining imparted dark brown stain of DAB 
precipitate that displayed the antibody-bound antigenic sites on the cells. The 
staining intensity and the percentage of positive cells were scored in a blind 
manner without prior knowledge of clinical information for any of the cases.  
 
All the immunohistochemistry results obtained from the TMAs 
constructed were scored in two manners - firstly, they were scored 
subjectively by human observers (CWO and MST); secondly, they were 
scored objectively by an automated scoring platform (Ariol SL50). The 
subsequent subsections describe the scoring criteria utilized. 
 
 
2.2.8.1 Human Observer Scoring Criterion 
 
Expression of Ki-67, p27 and p53 was considered positive if distinct nuclear 
staining was observed in the cancer cells. They were then classified semi-
quantitatively in four-tiered levels, negative (0%), low (<25%), moderate (≥25 
to 50) and high (>50%), corresponding to their percentage of nucleus stained. 
Expression of CK7, CK20, COX-2, SOX-2 and OCT-4 was considered 
positive if the cytoplasm of the cancer cells was stained. For COX-2, they 
were classified semi-quantitatively in four-tiered levels, negative (0%), low 
(<25%), moderate (≥25 to 50) and high (>50%), corresponding to their 
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intensity of staining observed in the cytoplasm. For CK7 and CK20, they were 
classified in two-tiered levels, negative (no staining observed) and positive 
(staining observed). For CD133, expression was considered positive if the 
membrane of the cancer cells was stained. Similar to cytoplasmic staining, 
they were classified semi-quantitatively in four-tiered levels, negative (0%), 
low (<25%), moderate (≥25 to 50) and high (>50%), corresponding to their 
intensity of staining observed in the membrane.  
 
 
2.2.8.2 Automated Computer Scoring Criterion 
 
For automated scoring, the TMA slides were digitized with the Ariol SL-50 
(Applied Imaging Inc., USA). Figure 5 shows a schematic representation of 
the processes involved in the Ariol SL-50 automated scoring. Each slide was 
scanned at 20x objective with three filters: red, green and blue that were 
subsequently converted into digital images via the included Ariol software. 
The program was trained to analyze objects of specific colour, size and shape 
for both nuclear and cytoplasmic staining for the six antibodies. After the 
initial program training calibration, the rest of the analysis was performed 
without human supervision. Positivity of the IHC markers expression was then 
recognised by the Ariol system, an absolute value of expression was 
subsequently provided by software. 
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From the values of expressions provided by the Ariol software, the cut-
off scores for determining positive expression for each protein were 
determined by receiver-operating characteristic curve analysis as outlined 
previously (Zlobec et al., 2007). Briefly, receiver-operating characteristic 
curves were constructed by plotting all possible sensitivity and specificity 
pairs. This allows selection of a threshold value that corresponds to maximum 
sensitivity with minimal loss of specificity. For receiver-operating 
characteristic analysis, scores above the cut-off were considered positive for 
protein expression and scores below as negative. Receiver-operating 
characteristic analysis also allows the identification of markers that possess 
discriminatory value for the determination of prognostic significance through 






Figure 5. A schematic representation of the processes involved in the 
automated pathology scoring system. 
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2.2.9 Statistical analysis 
 
To test for correlations between the clinical features and the incidence of a 
respective mutation or immunohistochemical expression, we used the Fisher's 
exact test and, whenever appropriate, the chi-square (χ2) test. Univariate Cox 
proportional hazards regression was performed to determine the prognostic 
value of various clinicopathological features and protein markers. To test for 
independence, the significant factors identified in univariate analyses were 
entered into a multivariate Cox regression model using a stepwise selection 
procedure. Survival curves were plotted using the Kaplan-Meier method and 
compared using the log-rank test.  
 
All statistical analyses were performed using the SPSS package (version 
15.0 for Windows, SPSS Inc., USA) with significance set at the 5% level. 
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CHAPTER 3: RESULTS  
 
3.1 Methodological Considerations  
 
The following sections describe the results on the methodological 
considerations of this thesis. Parts of following sections are based on 
Publications I and II. 
 
 
3.1.1 Comparisons between Different Methods of DNA Extraction  
 
In the set of ten samples, the total success rate for extracting DNA with Gentra 
Puregene, Qiagen DNAeasy and the laboratory-developed Proteinase K 
methods were 87%, 50% and 83%, respectively (Table 6). When analyzed on 
a per case basis, the success rates were 90%, 60% and 90%, respectively 
(Table 6). Thus, of the three methods, Gentra Puregene and the Proteinase K 
method were more efficient in DNA extraction. However, when purity of 
DNA was taken into consideration, the Gentra Puregene method had the 
highest success in extracting good grade DNA from the formalin-fixed 




Table 6. Comparison of the three protocols for quantity and quality of 
extracted DNA. Case success is defined for each protocol as the percentage of 
samples where at least one of the triplicate sample produced viable DNA 










Time taken to 
complete  2 days 1 day 2 days 
Successful 
extractions  26/30 (87%) 15/30 (50%) 25/30 (83%) 
Case success  9/10 (90%) 6/10 (60%) 8/10 (90%) 
DNA (ng/µl) Minimum value 547 150 236 
 Maximum value 1,636 1,050 1,814 
 Mean 1091 600 1025 
Purity 
 
 20/26 (76%) 10/15 (66%) 6/25 (24%) 
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3.1.2 Availability of DNA and Antigenic Sites from Formalin-Fixed 
Paraffin-Embedded Tissues 
 
As shown in Figure 6A, the DNA extracted from the archival formalin-fixed 
paraffin-embedded tissues exists primarily as fragmented nucleic acids of less 
than 300bp. PCR amplifiable DNA is obtainable from these archival formalin-
fixed paraffin-embedded tissues below that threshold. The PCR product is able 
to produce a sharp single band with no non-specific amplification (Figure 6B). 
As shown in Figure 7A, amplifiable product of up to 189bp can be obtained 
from 37.8% of the formalin-fixed paraffin-embedded tissues blocks. No 
correlation between amplification success and age of the blocks was observed 





Figure 6. Electrophoresis results of DNA extracted from legacy collection. 
(A) Crude DNA extracted from the archival FFPE exists primarily as 
fragmented nucleic acids of less than 300bp. (B) PCR amplifiable DNA is 
obtainable from these archival FFPE below that threshold. 
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Figure 7. PCR amplification efficacy of the DNA extracted from the 
legacy collection. (A) The chart shows that amplifiable products of up to 
189bp are available from 37.8% of the formalin-fixed paraffin-embedded 
tissues. (B) The amplification success is not associated with the age of the 
blocks (calculated from time of fixation to time of DNA extraction). 
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For evaluating the preservation of the antigenic sites of archival 
formalin-fixed paraffin-embedded tissues blocks, the TMA constructed for 
this part of the study constituted multiple tissue-types (both normal and 
tumour). Hence, some of the protein markers chosen were specific for a tissue-
type – such as the prostate specific antigen (PSA). Our results revealed that all 
the protein markers show the expected expression (Figure 8), both in relation 
to tissue specificity, as well as the expected subcellular localization. For 
instance, the PSA marker was only expressed in the prostate tissue, while the 




Figure 8. Representative expressions of protein markers assessed in the 
legacy collection. The expected expression indicates that the antigenic sites of 
archival formalin-fixed paraffin-embedded tissues blocks are intact and 
preserved. The figure above shows expression of (A) CK7; (B) Ki67; (C) p53; 
(D) CK20; (E) p27; and (F) COX-2. Image magnifications are at 20× and 40×.  
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3.1.3 Concordance between Observer and Automated Scoring 
 
Human visual and computer-assisted scoring was in agreement (all kappa 
values > 0.8; Table 7). In Table 8, the comparison between the non-matching 
cases is presented as percentage of disagreement in terms of over or under 
estimation. The majority of the non-matching cases for the cytoplasm-staining 
antibodies indicated that computer-assisted scoring was higher – 63.9% for 
CK7; 100% for CK20; 94.9% for COX-2.  In contrast, the reverse was 
observed for the nuclear-staining antibodies. Majority of the non-matching 
cases were scored lower by the computer-assisted method – 82.5% for Ki-67; 
94.3% for p27; 61.9% for p53. 
 
To determine if the scorings between the human visual and computer-
assisted methods result in any discrepancies in the statistical analysis of 
prognostic significance, the expression of all studied markers was assessed for 
association with age, gender, ethnicity, AJCC staging, primary tumour site, 
tumour size and histological grade. In both human visual and computer-
assisted scoring, only AJCC staging was found to be significantly associated 
with expression of CK7, CK20, COX-2 and p53 (Table 9). No other 
significant factors were found to be associated with survival in relation to 
markers expression. Both types of scoring predicted the similar set of 




Table 7. Level of agreement between human visual and computer-assisted 











    
 
CK7 Cytoplasmic 0.91 0.892-0.924 <0.001 
CK20 Cytoplasmic 0.98 0.976-0.983 <0.001 
COX-2 Cytoplasmic 0.84 0.809-0.866 <0.001 
Ki67 Nuclear 0.94 0.921-0.945 <0.001 
p27 Nuclear 0.98 0.98-0.986 <0.001 
p53 Nuclear 0.96 0.959-0.964 <0.001 
    
 




Table 8. Nature of disagreement between human visual and computer-
















    
CK7 Cytoplasmic 63.9 36.1 
CK20 Cytoplasmic 100 0 
COX-2 Cytoplasmic 94.9 5.1 
Ki67 Nuclear 17.5 82.5 
p27 Nuclear 5.7 94.3 
p53 Nuclear 38.1 61.9 




Table 9. Comparison of immunohistochemical markers expression in 
relation to clinical pathological features. 
 
















1.00 0.85 1.00 <0.01 0.49 0.69 0.53 
CK7 Computer-
assisted 
0.22 0.63 0.91 <0.01 0.09 0.63 0.23 
Human 
visual 
0.06 0.35 0.46 <0.01 0.26 0.93 0.91 
CK20 Computer-
assisted 
0.11 0.28 0.61 <0.01 0.31 0.91 0.98 
Human 
visual 
0.52 0.32 0.32 <0.01 0.75 0.28 0.24 
COX-2 Computer-
assisted 
0.07 0.05 0.06 <0.01 0.37 0.34 0.66 
Human 
visual 
0.42 0.08 0.8 0.88 0.93 0.61 0.34 
Ki67 Computer-
assisted 
0.89 0.23 0.52 0.79 0.87 0.05 0.32 
Human 
visual 
0.71 0.36 0.47 0.21 0.39 0.2 0.4 
p27 Computer-
assisted 
0.99 0.19 0.72 0.26 0.25 0.49 0.46 
Human 
visual 
0.44 0.58 0.86 <0.01 0.66 0.17 0.48 
p53 Computer-
assisted 
0.51 0.74 0.92 <0.01 0.51 0.67 0.18 
p-values in bold are statistically significant 
Groups compared: 1<60 vs ≥60; 2Chinese vs Malay vs Indian vs Others; 3A vs 
B vs C vs D; 4Colon vs Rectal; 5<5cm vs ≥5cm; 6Well vs Moderately vs 
Poorly differentiated 
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3.1.4 Time Required for Generating Pathological Scoring and 
Reproducibility of Results 
 
Computer-assisted method took less time to generate pathological scoring 
when the number of cores analysed were 20 and above (Figure 9). The timing 
taken for the computer-assisted method was also more consistent (around 2 
minutes per 10 cores). In contrast, the timing for human scoring was consistent 
only in the first 50 cores, after which the timing appeared to double (Figure 9). 
 
Both the machine and human scoring showed consistent 
reproducibility of pathological scorings (Table 11). The intraobserver 





Table 10. Univariate analysis for survival in relation to expression of 
immunohistochemistry markers. 
 




95% CI p  Hazard 
Risk 
Ratio1 
95% CI p 
CK7 2.02 1.82-2.32 <0.01  2.02 1.84-2.35 <0.01 
CK20 1.47 1.36-1.48 <0.01  1.48 1.36-1.48 <0.01 
COX-2 0.91 0.8-1.02 0.21  1.01 0.81-1.04 0.48 
Ki67 1.01 0.97-1.03 0.94  1.01 0.95-1.03 0.79 
p27 0.87 0.86-0.98 0.04  0.88 0.86-0.97 0.05 
p53 1.51 1.34-1.55 <0.01  1.49 1.33-1.51 <0.01 
CI=confidence interval; p-values in bold are statistically significant 





Table 11. Extent of disagreement in reproducibility of results between 















Human visual (week 
0 vs week 1) 
11 0.81 0.89-0.92 <0.01 
Intra-
observer Computer-assisted 
(week 0 vs week 1) 
2 0.98 0.97-0.98 <0.01 
Human visual vs 
computer-assisted  
(at week 0) 
6 0.97 0.96-0.99 <0.01 
Inter-
observer Human visual vs 
computer-assisted  
(at week 1) 
12 0.77 0.76-0.98 <0.01 
 p-values in bold are statistically significant 
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Figure 9. Comparison of time taken for pathological scoring analysis 
between human-observer method and computer-assisted method. The 
timing taken for the computer-assisted method was also more consistent 
(around 2 minutes per 10 cores) 
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3.2 Biological Considerations 
 
The following sections describe the results on the biological considerations of 
this thesis. Parts of following sections are based on Publication III. 
 
 
3.2.1 Protein Expression of Cancer Stem-Cell Markers 
 
The representative immunohistochemical stains for the three cancer stem-cell 
markers investigated in this study are shown in Figure 10. As expected, 
CD133 expression was localized to the glandular-luminal surface of tumour 
epithelial cells when present. Similar to previous study (Horst et al., 2009a), 
the intraglandular debris of shed tumour cells also showed CD133 staining. 
CD133 expression in the normal colonic mucosa was absent in the majority of 
cases or was very mild and focal in intensity in the remainder. For both OCT-4 
and SOX-2 expression, diffuse staining expression was observed in the 
cytoplasmic compartment of tumour epithelium when present. Similar staining 
patterns of OCT-4 and SOX-2 in rectal carcinomas have been recently 
reported (Saigusa et al., 2009). Mild cytoplasmic staining was observed in the 







Figure 10. Representative immunohistochemical staining for cancer stem 
cell markers in colorectal tumour tissues. As shown in the Figure above, 
CD133 staining is localized to the glandular-luminal surface of the tumour 
epithelial (A, D). Diffuse expression of SOX-2 (B, E) and OCT-4 (C, F) are 
localised to the cytoplasmic compartment of the tumour epithelium. Image 
magnifications are at 20× and 40×. 
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3.2.2 Selection of Protein Markers with Discriminatory Power for 
Prognostic and Predictive Significance 
 
As described in the Methods section, the selection of cut-off scores for 
defining positive protein expression was based on receiver operating 
characteristic curve analysis against five-year survival. The frequency of 
positive expression for each marker is shown in Table 12. Using values 
derived from the area under the receiver-operating characteristic curve, 
markers with area under the receiver operating characteristic curve values 
above 0.5 indicate significant discriminatory power for survival. The three 
cancer stem-cell markers CD133, OCT-4, SOX-2 were all identified as having 
discriminatory power (area under the receiver operating characteristic curve 
value > 0.5). A total of 27%, 39% and 48% of patients were classified as 
showing positive expression for CD133, OCT-4 and SOX-2, respectively. 
Amongst the six other commonly studied protein markers in colorectal cancer, 
only p27 expression was identified as having significant discriminatory power 




Table 12. Frequency of positive expression of protein markers using cut-

















CD133 0.614 10 137 (27) 
OCT-4 0.665 10 195 (39) 
SOX-2 0.597 10 242 (48) 
CK7 0.492 30 171 (34) 
CK20 0.402 25 368 (73) 
COX-2 0.472 35 392 (78) 
Ki-67 0.434 50 350 (70) 
p27 0.589 45 314 (62) 
p53 0.474 50 271 (54) 




Table 13. Correlation matrix showing relationships between the 
expressions of each protein marker. 
 
Marker CD133 CK7 CK20 COX-2 Ki-67 OCT-4 p27 p53 
CD133         
CK7 -0.04        
CK20 -0.68* 0.12       
COX-2 -0.01 0.23* 0.05      
Ki-67 -0.01 0.13 0.14 -0.19     
OCT-4 0.10 0.04 -0.11 0.01 -0.02    
p27 0.04 0.07 -0.05 -0.06 -0.02 0.07   
p53 -0.04 0.18 0.09 0.17 0.39* 0.06 -0.02  
SOX-2 0.24* -0.15 -0.25* -0.06 -0.03 0.31* -0.09 0.03 
Kendall’s ranking coefficients greater than 0.2 are statistically significant at p 
< 0.05; two-tailed tests 
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3.2.3 Associations Between Markers’ Expression and Clinicopathological 
Features 
 
Correlations between the expressions of the studied markers are shown in 
Table 13. Similar to previous reports (Ricci-Vitiani et al., 2007; Horst et al.,  
2009a), a strong inverse correlation was found between the expression of 
CD133 and CK20 (Kendall’s ranking coefficient = -0.68, P<0.001). The 
immunohistochemical expression of CD133 and OCT-4 were both positively 
associated with expression of SOX-2 (Kendall’s ranking coefficient of 0.24 
and 0.31, respectively). 
 
 Associations between clinicopathological features and expression of 
the three cancer stem cell markers are shown in Table 14. The expression of 
all three cancer stem cell markers showed significant associations with higher 




3.2.4 Prognostic Significance of Protein Expression 
 
Table 15 shows the results of univariate analysis for the prognostic 
significance of clinicopathological features and protein expression in patients 
treated by surgery alone (n=310) or with 5-FU based adjuvant chemotherapy 
(n=191). As expected, older patient age, poor histological grade, higher 
 69 
tumour stage and the presence of lymphatic, perineural and vascular invasion 
were all associated with worse survival in patients treated by surgery alone. 
CD133, OCT-4 and SOX-2 expression was also strongly associated with poor 
prognosis in patients treated by surgery alone, whereas p27 expression was a 
marker of good prognosis. All three cancer stem cell markers were also  
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Table 14. Associations between expression of cancer stem cell markers 













































































































CI: Confidence intervals; OR: Odds ratio; NS: Not significant 
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Table 15. Univariate disease-specific survival analysis for 
clinicopathological features and protein markers. 
 
 Surgery alone (n=310)  Chemotherapy (n=191) 
Feature HR 95% CI P  HR 95% CI P 
        Clinicopathological        
  Gender (female vs male) 1.05 0.68-1.35 NS  0.88 0.79-1.33 NS 
  Age (≥60 yrs vs <60 yrs) 1.88 1.21-2.90 0.005  1.24 0.79-1.94 NS 
  Ethnicity (Chinese vs non-Chinese) 0.65 0.34-1.13 NS  0.98 0.49-1.95 NS 
  Grade (poor vs well/moderate)  1.97 1.26-3.01 0.003  1.06 0.51-2.21 NS 
  Stage (III/IV vs I/II) 3.96 2.83-5.54 <0.001  2.54 1.34-4.80 0.004 
  Site (colon vs rectal) 0.66 0.46-0.97 0.034  0.89 0.55-1.45 NS 
  Tumour size (≥5cm vs <5cm) 0.96 0.69-1.33 NS  1.26 0.81-1.98 NS 
  Lymphatic invasion (yes vs no) 2.14 1.23-3.71 0.007  1.77 0.93-3.34 NS 
  Perineural invasion (yes vs no) 2.46 1.33-4.56 0.004  2.02 0.88-4.65 NS 
  Vascular invasion (yes vs no) 2.21 1.31-3.72 0.003  1.59 0.89-2.84 NS 
Protein expression       
 
  CD133 (positive vs negative) 1.89 1.35-2.64 <0.001  2.18 1.39-3.43 0.001 
  OCT-4 (positive vs negative) 2.20 1.53-3.16 <0.001  2.01 1.21-3.34 0.007 
  SOX-2 (positive vs negative) 1.72 1.24-2.39 0.001  1.71 1.09-2.72 0.02 
  CK7 (positive vs negative) 0.77 0.55-1.09 NS  1.09 0.68-1.73 NS 
  CK20 (positive vs negative) 1.53 0.92-2.09 NS  1.19 0.77-1.81 NS 
  COX-2 (positive vs negative) 1.01 0.58-1.24 NS  0.99 0.81-1.54 NS 
  Ki-67 (positive vs negative) 0.99 0.49-1.13 NS  1.54 0.68-2.10 NS 
  p27 (positive vs negative) 0.65 0.47-0.89 0.008  0.74 0.49-1.17 NS 
  p53 (positive vs negative) 0.93 0.65-1.31 NS  0.95 0.58-1.63 NS 
CI: Confidence intervals; HR: Hazard risk ratio; NS: Not significant 
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prognostic for worse survival in the subgroup of patients treated with 
chemotherapy. 
 
 The significant parameters identified from univariate analysis were 
tested for independent prognostic value in a multivariate Cox regression 
analysis model. Patient age, tumour stage, vascular invasion and the 
expression of CD133, OCT-4 and p27 were all found to be independent 
prognostic factors in patients treated by surgery alone (Table 16). For patients 
treated with chemotherapy, only tumour stage and the expression of CD133 
and OCT-4 were independent factors for survival.  
 
 The survival of patient subgroups classified according to the 
expression of protein markers was evaluated using Kaplan-Meier analysis. 
Patients treated by surgery alone and with CD133+/ OCT-4+/ p27- tumours 
showed a mean survival of just 15 months compared to 50 months for those 





Table 16. Multivariate (adjusted) analysis for disease-specific survival 
according to clinicopathological features and protein expression. 
 
Feature HR 95% CI P 
Surgery alone (n=310)   
 
  Age ≥ 60 years 1.89 1.19-2.99 0.007 
  Tumour stage III/ IV 3.32 2.33-4.74 <0.001 
  Lymphatic invasion positive 1.05 0.58-1.92 NS 
  Perineural invasion positive 1.67 0.84-3.31 NS 
  Vascular invasion positive 1.93 1.08-3.45 0.026 
  CD133 positive 1.54 1.07-2.21 0.023 
  OCT-4 positive 2.17 1.47-3.2 <0.001 
  SOX-2 positive 1.03 0.72-1.48 NS 
  p27 positive 0.52 0.37-0.73 <0.001 
Chemotherapy (n=191)    
  Age ≥ 60 years 1.44 0.91-2.30 NS 
  Tumour stage III/IV 2.45 1.27-4.73 0.008 
  Lymphatic invasion positive 0.90 0.39-2.07 NS 
  Perineural invasion positive 2.13 0.80-5.64 NS 
  Vascular invasion positive 1.55 0.77-3.12 NS 
  CD133 positive 2.18 1.35-3.52 0.001 
  OCT-4 positive 1.40 1.08-2.39 0.021 
CI: Confidence intervals; HR: Hazard risk ratio; NS: Not significant 
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3.2.5 Predictive Significance of Protein Expression 
 
Kaplan-Meier analysis was used to compare the survival rates of stage III 
patients treated with or without chemotherapy and classified according to the 
expression of cancer stem cell proteins (Figure 11). 5-FU based chemotherapy  
conferred an apparent survival benefit to patients regardless of their expression 
status for OCT-4 or SOX-2 (Figure 11C-11F). Although patients with CD133- 
tumours gained significant benefit from chemotherapy (Figure 11A), no 
survival benefit was seen for patients with CD133+ tumours (Figure 11B), 
suggesting that CD133 expression is a predictive marker for survival benefit 
from 5-FU based adjuvant chemotherapy.   
 
Clinical data for response to chemotherapy was available for 44 stage IV 
patients. Using standardized criteria, half of these patients (n=22) showed 
clinical response to treatment and the other half did not (n=22). Of the patients 
with CD133+ tumours, only 7/24 (29%) showed response compared to 15/20 
(75%) of the patients with CD133- tumours (P=0.006). None of the other 





Figure 11. Kaplan-Meier survival analysis of stage III colorectal cancer 
patients. Broken lines represent patients treated by surgery alone, while 
continuous lines represent patients treated with adjuvant chemotherapy in 
addition to surgery. The figure above shows the analysis for survival in 
association with negative (A, C, E) or positive (B, D, F) expression of CD133, 
OCT-4 and SOX-2, respectively. An apparent survival benefit from 
chemotherapy is observed for all patient subgroups except those with positive 
CD133 expression. 
 76 
3.2.6 KRAS Mutational Analysis 
 
KRAS mutations occurred in 35 (30%) of the 117 primary colorectal 
carcinomas, consistent with mutation frequencies reported in the literature 
(Nosho et al., 2008; Brink et al., 2003; Samowitz et al., 2005a). The most 
common mutation was codon 12 aspartate-for-glycine (12/35; 34%), followed 
by codon 12 valine-for-glycine (5/35; 14%). Nine of the 35 (25%) cases were 
unstable for BAT26. A slight relationship was observed between KRAS 
mutation and tumour size (p=0.08). No other significant relationships with 
clinicopathological features or cancer stem cell markers expression were 




3.2.7 BRAF Mutational Analysis 
 
Of the 117 cases, 11 (9%) exhibited BRAF mutations, in line with the data 
reported in the literature (Samowitz et al., 2005; Nosho et al., 2008; Ogino et 
al., 2009). All 11 cases failed to respond to 5-FU therapy. One out of the 11 
(9%) cases was unstable for BAT26. Significant relationships were seen 
between the BRAF mutation and tumour location as well as perinerual 
invasion. This is in line with previously reported data in larger colorectal 
cancer cohort (Baldus et al., 2010). A slight association with survival was 
observed (P=0.064). No other significant relationships with 
clinicopathological features or cancer stem cell markers expression were 
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CI: Confidence intervals; OR: Odds ratio; NS: Not significant 
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3.2.8 Microsatellite Instability Analysis 
 
A total of 10 (9%) of the 117 cases were unstable for BAT26. This is 
consistent with previously reported data in colorectal cancer (Samowitz et al., 
2005b). There is a significant relationship of BAT26 instability with tumour 
size (p=0.04) and a slight association with tumour grade (p=0.08). No other 
significant associations with clinicopathological features or cancer stem cell 
markers expression were observed (Table 17). 
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CHAPTER 4: DISCUSSION 
 
4.1. Availability of DNA and Antigenic Sites from Formalin-Fixed 
Paraffin-Embedded Tissues 
 
Fixation of tissue specimens by formaldehyde often results in DNA binding 
and subsequent disruption of the native DNA strand (Cao et al., 2003). In our 
study, we showed that DNA samples to be studied with the PCR technique do 
not required fully intact genomic DNA. We have shown that a certain amount 
of damage can be tolerated as long as TaqDNA polymerase activity is not 
disrupted. The main disruptive agent for the lack of amplifiable DNA 
available in formalin-fixed paraffin-embedded tissues might be the 
contaminating residue from the fixation or extraction procedures (Cao et al., 
2003). In order to assure that the extracted DNA is free from RNA and other 
contaminating material, the absorbance reading at 260/280 nm should be over 
1.8. Recent study has shown that cycle threshold values from real-time 
quantitative PCR are better indicators for gauging the suitability of formalin-
fixed paraffin-embedded tissues samples for PCR than spectrophotometric 
concentrations (Ang et al., 2008). This could be main reason that we are only 
able to extract up to a maximum of 50% of usable DNA from the formalin-
fixed paraffin-embedded tissues despite having spectrophotometric values of 
1.8 at 260/280nm wavelength. 
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 It is generally assumed that long-term storage as well as poor storage 
conditions of the paraffin blocks, such as fluctuating temperature and high 
humidity, was main causes for low quantifiable DNA from the formalin-fixed 
paraffin-embedded tissues (Bresters et al., 1994; Cronin et al., 2004). 
Interestingly, we observed no correlation of quantifiable DNA with age of 
paraffin blocks that were stored in the tropical climate of high temperature and 
humidity.  This suggests that the ability to extract amplifiable DNA might not 
necessarily be associated with poor storage conditions. Additionally, a number 
of studies have reported observations that the long-term storage of formalin-
fixed paraffin-embedded samples appears to have no negative effect on 
downstream applications such as PCR (Coudry et al., 2007; Schweiger et al., 
2009). Taken together, it is possible that the lack of amplifiable DNA might be 
due to the rate of tissue fixation and embedment to a certain degree. In our 
study, we have showed that the antigenic epitopes for antibody reactions in 
immunohistochemistry are not disrupted by formalin fixation. All 
immunohistochemical expressions produced expected results from our 
validation samples. These observations also indicate that long term storage 
and storage conditions of paraffin blocks might not affect 
immunohistochemistry. 
 
In summary, the decreased availability of DNA from formalin-fixed 
paraffin-embedded tissues might not be totally dependent on storage durations 
and conditions. Other possible factors, such as rate of formalin fixation and 




4.2 Concordance between Observer and Automated Scoring 
 
Immunohistochemistry has become a common method in evaluating 
expression of tumour-associated proteins in relation to cancer development 
and prognosis (McCabe et al., 2005; Kirkegaard et al., 2006; Parker et al., 
2008). In addition, the determination of IHC expression levels has progressed 
towards a more quantitative type of assessment. However, this process was 
found to be time-consuming. In this study, we have shown that automated 
machine scoring could be a reliable alternative to human scoring. We have 
demonstrated that the pathological scoring results from machine are consistent 
and in-agreement with human scoring in identifying potential prognostic 
markers. Results from weighted Kappa analyses have also demonstrated 
significant correlation between machine and human scoring. When we 
examined the differences within the non-matching cases, we found out that the 
machine tends to accord higher scores to cytoplasm-staining antibodies. For 
cytoplasm-staining antibodies, the staining intensity of the cytoplasm is 
usually used as criteria for scoring. In theory, machines are able to assess the 
colour intensity more accurately and provide a direct measurement of the 
colour intensity from the hue, saturation and intensity index (Parker et al., 
2008). In contrast, human evaluate the colour intensity in a more 
approximated, subjective manner (Gegenfurtner et al., 2003). Our results, 
therefore, suggest that human tend to underestimate the colour intensity in 
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cytoplasm-staining antibodies. For nuclear-staining antibodies, the number of 
positively-stained nucleus was used as a criterion for grading. The machine 
was calibrated to pick out the shape and colour of a positively-stained nucleus 
accurately. Our results showed that the majority of non-matching cases were 
scored lower by machine (Table 8). This suggests that, in general, human 
scoring of nuclear expression may be overestimated.  
 
When comparing the performance of human (subjective) IHC scoring 
with machine-driven (objective) methods, the jury is still out as to which 
should be the true gold-standard. In our study, we chose to take the clinical 
(prognostic) value of known markers as the gold-standard. In other words, the 
closer the method is to show the prognostic significance (survival) of a given 
antibody, the better it would be. In assessing survival outcome in relation to 
immunohistochemical expression, both human and machine identified the 
same set of potential prognostic factors. Univariate analysis showed that both 
methods were predicting the same outcome as each other (Table 10). The 
concordance of the outcome trends between human and machine, along with 
the kappa-value obtained from the scoring, suggest that machine scoring is a 
viable alternative to human scoring. On the other hand, the results also 
highlight that automated scoring may provide a practical advantage in terms of 
time-saving, but not an analytical advantage, as the comparative results with 
the subjective, human scoring are very similar (both well within statistical 
significance). Indeed, the combination of the tissue microarray platform and a 
machine-based, automated scoring system for high-throughput biomarker 
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studies, can reduce the time-consuming process of human scoring (Walker et 
al., 2006; Parker et al., 2006). With an automated system, the image scanning 
and the assessment of tissue microarray slides can be left running on its own 
without any human supervision. Human scoring can be subjected to external 
factors or distractions, such as ambient lighting, fatigue and noise levels of 
surroundings. Compared to the machine, human could require more time to 
score pathological slides when there were more materials to be assessed, as 
evident in our study (Figure 9). There are limitations to using an automated 
scoring analysis. Firstly, most of the current image analysis systems are based 
on pre-determined object orientated markers, such as shape and size, and this 
has to be carefully calibrated by a qualified pathologist. Secondly, the 
additional time taken to calibrate the markers for the machine might outweigh 
the time saving advantage, especially in studies with smaller sample size. 
 
We also examined the reproducibility of the pathological scores in our 
study. The intraobserver variation was higher in human visual scoring 
(k=0.81) compared to computer-assisted scoring (k=0.98). As seen in Table 
11, when the scoring was conducted again, the percentage of disagreement 
between human visual and computer-assisted scoring increased from 6% to 
12%. Nevertheless, the level of agreement between human visual and 
computer-assisted scoring was still strong (k=0.77; Table 11). However, it 
must be noted that we have only used a single machine in our study, and thus 
we cannot analyse inter-machine reproducibility. In any case, previous results 
have shown that the agreement between two different Ariol-SL50 machines 
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was highly consistent (Turbin et al., 2008). Hence, this suggests that 
computer-assisted pathological scoring is more consistent and reproducible 
than human visual scoring. 
 
In summary, our study has shown that a fully automated computer-
assisted scoring system, although did not provide any analytical advantage, 
can be used for high-throughput biomarker analyses in a manner that is more 
practical and timesaving. 
 
 
4.3 Prognostic and Predictive Significance of Cancer Stem Cells in 
Colorectal Cancer 
 
Recent reports have suggested the existence of a cancer stem cell compartment 
that can self-renew and differentiate into mature and diverse cancer cells 
capable of tumour initiation, growth, invasion and metastasis (Reya et al., 
2001; Baba et al., 2009). Because cancer stem cells divide very slowly, it is 
believed they may be resistant to most of the current chemotherapies that 
target differentiated or highly proliferating tumour cells (Boman and Huang, 
2008). The results from several in vitro studies on various cancer cell lines 
support this concept (Ma et al., 2008; Chen et al., 2008), although to date 
there has not been any evidence from clinical studies. In the present work, we 
provide the first evidence that expression of the cancer stem cell marker 
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CD133 is associated not only with poor prognosis in colorectal cancer, but 
also with a poor response of these tumours to 5-FU based chemotherapy. 
 
Three studies have isolated tumour initiating cell populations from 
colorectal cancer that express the surface marker CD133 and possess apparent 
“stem cell-like” properties (Ricci-Vitiani et al., 2007; Kojima et al., 2008; 
Horst et al., 2009a). Similar to previous reports in colorectal cancer (Horst et 
al., 2009a; O’Brien et al., 2007), CD133 expression in the present study was 
found to correlate inversely with expression of the intestinal epithelial 
differentiation marker CK20 (Table 13) and to localize to the glandular-
luminal surface of tumour epithelial cells (Figure 10A). Using receiver-
operating characteristic analysis, we estimated that 27% of colorectal cancers 
were CD133+. This compares to earlier reports for the frequency of CD133+ 
colorectal cancer as 25% (Horst et al., 2009a) and 15% (Kojima et al., 2008). 
CD133 expression was an independent prognostic indicator in the present 
study (Table 16), confirming the results from previous studies in colorectal 
cancer (Kojima et al., 2008; Horst et al., 2009a). OCT-4 expression was 
shown here for the first time to have independent prognostic significance, 
particularly in patients treated by surgery alone (Table 16). The good 
prognosis associated with p27 expression confirms previous reports with this 
marker (Zlobec et al., 2008). 
 
 The major finding of the present study was that colorectal cancers with 
the CD133+ immunophenotype show resistance to 5-FU based chemotherapy. 
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Two separate lines of evidence were obtained in support of this. Firstly, stage 
III colorectal cancer patients with CD133+ tumours did not show any apparent 
survival benefit from chemotherapy (Figure 11B), in contrast to patients with 
CD133- tumours (Figure 11A) and with all OCT-4 and SOX-2 expression 
subgroups (Figure 11C-11F). Secondly, stage IV patients with CD133+ 
tumours showed significantly less clinical response to chemotherapy (29%) 
compared to patients with CD133- tumours (75%, P<0.006). Together, these 
results suggest that CD133 expression could be a clinically useful marker of 
chemoresistance in colorectal cancer and perhaps also in other tumour types. 
   
Our observations in a clinical tumour series concur with recent 
findings from an in vitro study in which 5-FU and oxaliplatin-resistant clones 
of the HT29 colorectal cancer cell line showed 16- and 30-fold increases, 
respectively, in CD133 expression compared to non-resistant cells (Dallas et 
al., 2009). These results suggest that CD133 expression may be predictive for 
a wide range of cytotoxic agents used in cancer treatment. Indeed, several 
other in vitro studies have reported chemoresistance of CD133+ ovarian 
cancer (Baba et al., 2009), glioblastoma (Liu et al., 2006) and hepatocellular 
carcinoma (Ma et al., 2008) cell lines to a variety of chemotherapeutic agents. 
The expression of CD133 has been used to isolate putative cancer stem cells 
from tumours of the liver (Suetsugu et al., 2006; Yin et al., 2007), pancreas 
(Hermann et al., 2007), prostate (Collins et al., 2005), brain (Singh et al., 
2004) and lung (Eramo et al., 2008), in addition to colorectal cancer. These 
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findings suggest that CD133+ subgroups from other tumour types may also be 
chemoresistant.  
 
In summary, tumour expression of the two cancer stem cells markers 
CD133 and OCT-4 was associated with worse survival of colorectal cancer 
patients. Our findings also show for the first time that CD133+ colorectal 
cancer tumours are more resistant to 5-FU based chemotherapy.  
 
 
4.4 Associations of Cancer Stem Cell Markers with KRAS, BRAF and 
Microsatellite Instability 
 
The development of colorectal cancer requires a multistep process 
characterized by the accumulation of genetic alterations. According to the 
traditional genetic model for colorectal tumourigenesis proposed by Fearon 
and Vogelstein (1990), KRAS mutations are a relatively early event in the 
development of colorectal cancers. Recent developments have link KRAS to 
the CIMP pathway of colorectal cancer development. Additionally, KRAS 
mutations have been demonstrated to show growth advantage in clonal 
expansions. These mutations are frequently found in 30 to 40% of colorectal 
cancer cases. In this study, we found that 30% of the cases have KRAS 
mutations. Numerous studies have tried to determine whether the presence of a 
KRAS mutation correlates with in colorectal cancer, but they have yielded 
conflicting results (Nosho et al., 2008; Samowitz et al., 2005a). In our study, 
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we did not observe any correlation of KRAS mutation with survival. More 
recently, studies have shown that colorectal cancer patients exhibiting KRAS 
mutations are not responding well to therapies with anti-EGFR antibodies 
(Lievre et al., 2006; Lievre et al., 2008; Di Fiore et al., 2007; Bibeau et al., 
2009). In our analysis, we did not observe any significant correlation between 
KRAS mutations and response to 5-FU treatment in stage III colorectal cancer 
patients. This suggests different testing might be required for predicting 
response to therapy administered to colorectal cancer patients. Our study, 
which previously assessed the predictive potential of cancer stem cells 
markers, suggests that CD133 might be a better predictor for response to 5-FU 
treatment. 
 
In this study, BRAF mutations were observed in 9% of the tumours, 
which correspond to the prevalence of 5% to 17% reported in the literature 
(Samowitz et al., 2000; Samowitz et al., 2005a; Nosho et al., 2008; Ogino et 
al., 2009). We observed significant associations between BRAF mutations and 
tumour location as well as perineural invasion. Interestingly, we also found 
significant association with poor survival in patients with BRAF mutation. 
This is similar to previous studies that showed worse prognosis in 
microsatellite stable patients with BRAF mutations (Baldus et al., 2010). 
Although the BRAF mutations are found more frequently in MSI unstable 
colorectal cancers, the frequency of MSI instability in BRAF mutated stage III 
cases are minimal in this study. Amongst the 11 cases with BRAF mutations, 
only one was microsatellite unstable. Due to the relative paucity of 
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microsatellite instability in sporadic colorectal cancers, we are unable to 
determine if microsatellite-stable tumours with the BRAF mutation have worse 
prognosis than stable tumours without this mutation. 
 
BAT26 alone was used as a generalized marker for microsatellite 
instability in this study. Studies have shown that this is sufficient for measure 
of microsatellite instability in tumours (Samowitz et al., 2005b; Bacani et al., 
2005). In our study, we observed 10% of BAT26 positive (microsatellite 
instable) in the colorectal tumours. We did not observe any significant relation 
between microsatellite instability and family history (Table 17).  
 
There were no associations observed between all three cancer stem cell 
markers with BRAF, KRAS or microsatellite instability (Table 17). These 
suggest that the cancer stem cells might be working in other pathways other 
than the CIN, CIMP or MSI pathways in colorectal tumourigenesis. 
Contrastingly, it also postulates that the fact that cancer stem cells may be 
common to all pathways. It is possible that several of these clonal events can 
be bypassed by other genetic or epigenetic aberrations in order to deliver the 
necessary biological consequences (Young, 2002). 
  
In summary, our findings suggested that patients with BRAF mutated 
tumours should be treated more aggressively, especially those with stage III. 
The poor prognosis associated with such tumours in our study suggested that 
current therapies are not specifically targeting mutated BRAF.  
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4.5 Conclusion and Future Directions 
 
In conclusion, the findings from this work indicated that amplifiable DNA was 
extractable from formalin-fixed paraffin-embedded tissue blocks as old as 50 
years of age. These DNA need not be fully intact to be amplification as 
contaminations during the extraction process are minimized. 
 
A high level of agreement between automated pathological scoring and 
manual observer scoring were demonstrated in this thesis. A fully automated 
computer-assisted scoring system, although did not provide any analytical 
advantage, is more time-effective and is suited for high-throughput biomarker 
analyses. 
 
The main finding of this study is that CD133 expression was found to 
possess predictive significance of chemoresistance in colorectal cancer 
patients. In addition, independent prognostic significance of p27 expression as 
well as CD133 and OCT-4 were observed with the latter also unreported to 
date.  
 
In our study, KRAS mutations did not yield any predictive advantage to 
treatment response for 5-FU treatment, suggesting that different markers are 
required for predicting response to different therapeutic agents. CD133 is 
indeed a better marker suited for predicting response for 5-FU treated cases.  
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The poor prognosis associated with BRAF mutated tumours in this 
study indicated that current therapies might not be specifically targeting 
mutated BRAF. 
 
Cancer stem cell markers are not limited to those that are outlined in 
this thesis, future studies can work on various to other cancer stem cell 
markers, such as Lgr5 or CD44, to further improve the understanding of role 
of cancer stem cells in tumour progression. In addition, the same model of 
analysis can be applied to future studies in other cancer types to compare the 
roles of the cancer stem cell markers in different carcinomas. 
 
This study allowed us to establish a clinical research platform that can 
hopefully continue to contribute to improve our understanding of prognosis 
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